Department of Epidemiology and Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Am J Cardiol. 2011 Sep 15;108(6):822-7. doi: 10.1016/j.amjcard.2011.04.034. Epub 2011 Jul 7.
Few data are available on factors associated with low adherence or early clopidogrel discontinuation after percutaneous coronary intervention (PCI). Patients (n = 284) were evaluated before hospital discharge after PCI to identify factors associated with low adherence to clopidogrel 30 days later. Adherence to daily medications before PCI was assessed using the 8-item Morisky Medication Adherence Scale (MMAS-8) and categorized as low (score <6), medium (score 6 to <8), or high (score 8). Low adherence to clopidogrel was defined as MMAS-8 score <6 (n = 21) or having discontinued clopidogrel (n = 11), which was ascertained during a 30-day interview after PCI. At 30 days after PCI, 11% of patients had low adherence to clopidogrel. Odds ratios (95% confidence intervals [CIs]) for low adherence to clopidogrel were 3.78 (1.09 to 13.1), 3.06 (1.36 to 6.87), 2.46 (0.97 to 6.27), and 3.36 (0.99 to 11.4) for patients who before PCI reported taking smaller doses of medication because of cost, had difficulty filling prescriptions, had difficulty reaching their primary physician, and were not comfortable asking their doctor for instructions, respectively. Odds ratios (95% CIs) for low clopidogrel adherence after PCI in patients with medium and low versus high adherence to daily medications before PCI were 6.13 (1.34 to 28.2) and 10.9 (2.46 to 48.7), respectively. The c-statistic associated with MMAS-8 scores before PCI for discriminating low clopidogrel adherence at 30 days after PCI was 0.733 (95% CI 0.650 to 0.852). In conclusion, adherence to daily medications before PCI may be a useful indicator for identifying patients who will have low clopidogrel adherence after PCI.
关于经皮冠状动脉介入治疗 (PCI) 后低依从性或早期氯吡格雷停药的相关因素,目前仅有少量数据。本研究入选了 284 例 PCI 术后出院前的患者,旨在明确与 30 天后氯吡格雷低依从性相关的因素。采用 8 项 Morisky 用药依从性量表 (MMAS-8) 评估 PCI 前的每日用药依从性,并分为低依从性(得分 <6)、中依从性(得分 6 至 <8)或高依从性(得分 8)。氯吡格雷低依从性定义为 MMAS-8 评分 <6(n = 21)或停药(n = 11),通过 PCI 后 30 天的访谈确定。PCI 后 30 天,11%的患者氯吡格雷依从性低。氯吡格雷低依从性的优势比(95%置信区间 [CI])分别为 3.78(1.09 至 13.1)、3.06(1.36 至 6.87)、2.46(0.97 至 6.27)和 3.36(0.99 至 11.4),分别对应于 PCI 前报告因费用而减少药物剂量、难以配药、难以联系主治医生和难以向医生咨询的患者。在中、低与高 PCI 前每日用药依从性患者中,PCI 后氯吡格雷低依从性的优势比分别为 6.13(1.34 至 28.2)和 10.9(2.46 至 48.7)。PCI 前 MMAS-8 评分预测 30 天后氯吡格雷低依从性的 C 统计量为 0.733(95%CI 0.650 至 0.852)。结论:PCI 前的每日用药依从性可能是识别 PCI 后氯吡格雷低依从性患者的有用指标。